Loading
Search products, companies, tests, and guides — go from query to quote request in one place.
Tests
A proprietary enzyme-linked immunosorbent assay for semi-quantitative detection of IgG antibodies against SARS-CoV-2 using the S1 domain of the spike protein, including the receptor binding domain (RBD).
Tests
A proprietary enzyme-linked immunosorbent assay for semi-quantitative detection of IgG antibodies against SARS-CoV-2 using a modified nucleocapsid protein (NCP) containing only diagnostically relevant epitopes.
Tests
A proprietary enzyme-linked immunosorbent assay for semi-quantitative detection of IgM antibodies against SARS-CoV-2 using a modified nucleocapsid protein (NCP) containing only diagnostically relevant epitopes.
Tests
A proprietary enzyme-linked immunosorbent assay for quantitative detection of IgG antibodies against SARS-CoV-2 using the S1 domain of the spike protein, including the receptor binding domain (RBD).
Glossary Term
Validation evidence that an assay detects the range of variants, genotypes, or serotypes it claims to cover. For evolving targets such as influenza or SARS-CoV-2, inclusivity statements carry a validation date and should be checked against circulating variant lists at procurement time.
Indicators
Molecular detection and typing of influenza A and B viruses.
Article
Research record from J Clin Med, 2026-09-11. PMID 42795842.
Tests
A proprietary serology assay that can be used to measure IgG antibodies against the SARS-CoV-2 nucleocapsid protein (N).
Tests
A proprietary serology assay that can be used to measure IgM antibodies against the SARS-CoV-2 nucleocapsid protein (N).
Tests
A proprietary serology assay that can be used to measure IgG antibodies against the SARS-CoV-2 S1 spike receptor-binding domain (RBD).
Tests
A proprietary serology assay that can be used to measure IgA antibodies against the SARS-CoV-2 spike protein (S).
Article
Research record from EJHaem, 2026-10-24. PMID 42927348.
